ARCH, Medicines Co. veterans raise $290 million for in-licensed obesity drugs

After scouring 200 companies’ pipelines — including a few overlooked pharma shelves — a new company backed by investment firm Population Health Partners and ARCH Venture Partners is launching with one of the most wide-ranging pipelines yet for obesity drug development.

Metsera came out of stealth mode Thursday with $290 million in seed and Series A financing. ARCH and Population Health Partners, which launched in 2020 and has several veterans from Pfizer and The Medicines Company on its team, led the round. F-Prime Capital, GV, Mubadala Capital, Newpath Partners, and SoftBank Vision Fund 2 were also part of the financing.

Metsera has already put that money to work: The New York startup licensed several drug candidates from South Korean biotech D&D Pharmatech, according to Endpoints and Korea Biomedical Review. Altogether, the deal is worth more than 1 trillion Korean won, or $740 million, in licensing fees and milestone payments.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In